All posts by: Michael Zand

About Michael Zand

Study: CAR T-Cell Therapy Highly Effective in High-Risk Chronic Lymphocytic Leukemia – AJMC.com Managed Markets Network

Continue reading

2017-10-20 NEWS

Study: CAR T-Cell Therapy Highly Effective in High-Risk Chronic Lymphocytic Leukemia
AJMC.com Managed Markets Network
CD19 CAR T cells are highly effective in high-risk patients with chronic lymphocytic leukemia (CLL) who have failed to respond to treatment with ibrutinib, a Bruton’s tyrosine kinase inhibitor, according to a study by Cameron J. Turtle, MD, and

and more »

Continue reading

2017-10-20 NEWS

ModernMedicine

Game-changing gene therapies present cost problems for health execs
ModernMedicine
The recent approval of two cell-based gene therapies has healthcare executives scratching their heads about ways to manage these anticipated costly drugs, say experts. In August, the FDA approved Novartis’s tisagenlecleucel (Kymriah), the first

and more »